Neuroscience & CNS
Part of Biotech - Drug Development
| Ticker | Company | Mkt Cap▼ | Price | Chg% | Volume |
|---|---|---|---|---|---|
 BIIB | Biogen Inc. Common Stock | $26.9b | $192.08 | -0.5% | 475.9K |
 RGC | Regencell Bioscience Holdings Limited Ordinary Shares | $14.4b | $28.29 | -1.0% | 37.0K |
 NBIX | Neurocrine Biosciences Inc | $12.9b | $157.72 | -0.4% | 612.0K |
 JAZZ | Jazz Pharmaceuticals, Inc. | $12.8b | $229.26 | +0.2% | 276.1K |
 AXSM | Axsome Therapeutics, Inc | $9.5b | $225.97 | -0.8% | 255.7K |
 PRAX | Praxis Precision Medicines, Inc. Common Stock | $9.0b | $316.05 | -7.7% | 156.1K |
 CYTK | Cytokinetics Inc. | $7.5b | $75.91 | +0.1% | 670.5K |
 PTCT | PTC Therapeutics, Inc. | $5.8b | $70.19 | -1.8% | 370.6K |
 ALKS | Alkermes Inc. plc | $5.7b | $37.32 | -0.4% | 842.8K |
 TGTX | TG Therapeutics, Inc. | $5.5b | $39.58 | +0.2% | 710.2K |
 XENE | Xenon Pharmaceuticals Inc | $5.3b | $53.49 | -1.6% | 236.6K |
 INDV | Indivior Pharmaceuticals, Inc. Common Stock | $4.2b | $36.54 | -0.6% | 463.6K |
 ACAD | Acadia Pharmaceuticals Inc. | $3.9b | $20.76 | -3.0% | 723.6K |
 DNLI | Denali Therapeutics Inc. Common Stock | $3.2b | $18.50 | -0.7% | 885.5K |
 ALMS | Alumis Inc. Common Stock | $3.1b | $20.97 | -8.3% | 663.7K |
 SUPN | Supernus Pharmaceuticals, Inc. | $2.8b | $48.49 | -1.9% | 263.4K |
 DFTX | Definium Therapeutics, Inc. Common Shares | $2.3b | $20.65 | -1.6% | 722.0K |
 STOK | Stoke Therapeutics, Inc. Common Stock | $2.0b | $28.95 | -3.8% | 243.2K |
 AMLX | Amylyx Pharmaceuticals, Inc. Common Stock | $1.8b | $12.82 | -3.5% | 534.1K |
 TSHA | Taysha Gene Therapies, Inc. Common Stock | $1.8b | $5.50 | -7.8% | 1.1M |
 HRMY | Harmony Biosciences Holdings, Inc. Common Stock | $1.8b | $29.84 | -0.8% | 227.5K |
 RAPP | Rapport Therapeutics, Inc. Common Stock | $1.6b | $35.30 | -4.8% | 112.6K |
 ATAI | AtaiBeckley Inc. Common Stock | $1.6b | $4.13 | +3.0% | 5.9M |
 BHVN | Biohaven Ltd. | $1.4b | $8.54 | -2.5% | 976.2K |
 MPLT | MapLight Therapeutics, Inc. Common Stock | $1.3b | $26.06 | -9.3% | 267.0K |
 GHRS | GH Research PLC Ordinary Shares | $1.2b | $21.58 | +0.9% | 296.2K |
 COLL | Collegium Pharmaceutical, Inc. Common Stock | $1.1b | $34.09 | +0.9% | 143.6K |
 ANNX | Annexon, Inc. Common Stock | $1.0b | $5.00 | -3.9% | 1.7M |
 LBRX | LB Pharmaceuticals Inc Common Stock | $0.9b | $27.43 | -7.5% | 99.6K |
 DRUG | Bright Minds Biosciences Inc. Common Stock | $0.9b | $74.28 | -4.1% | 258.4K |
 TBPH | Theravance Biopharma, Inc. | $0.9b | $16.28 | +0.4% | 175.8K |
 ANRO | Alto Neuroscience Inc. | $0.9b | $21.94 | -4.5% | 279.3K |
 RLMD | Relmada Therapeutics, Inc. Common Stock | $0.8b | $6.42 | -6.9% | 1.3M |
 PRTA | Prothena Corporation plc Ordinary Shares | $0.6b | $9.71 | -0.5% | 358.1K |
 AQST | Aquestive Therapeutics, Inc. Common Stock | $0.5b | $4.21 | +0.8% | 1.6M |
 CTNM | Contineum Therapeutics, Inc. Class A Common Stock | $468.2m | $13.06 | -4.8% | 77.0K |
 OVID | Ovid Therapeutics Inc. Common Stock | $467.2m | $2.46 | -6.3% | 845.9K |
 VNDA | Vanda Pharmaceuticals Inc. | $411.3m | $6.09 | -3.0% | 622.6K |
 NMRA | Neumora Therapeutics, Inc. Common Stock | $411.0m | $1.75 | -5.2% | 438.5K |
 NGEN | NervGen Pharma Corp. Common stock | $314.0m | $3.69 | +3.6% | 97.1K |
 AVXL | Anavex Life Sciences | $312.3m | $2.88 | -1.2% | 525.2K |
 ACIU | AC Immune SA | $308.4m | $2.84 | +1.8% | 134.3K |
 NERV | Minerva Neurosciences, Inc | $282.3m | $4.86 | -6.7% | 75.8K |
 ELDN | Eledon Pharmaceuticals, Inc. Common Stock | $264.0m | $3.58 | -5.9% | 628.6K |
 ALEC | Alector, Inc. Common Stock | $263.8m | $2.15 | -0.2% | 445.3K |
 HELP | Cybin Inc. Common Stock | $257.5m | $4.47 | -4.3% | 685.6K |
 IKT | Inhibikase Therapeutics, Inc. Common Stock | $248.2m | $1.63 | -6.1% | 530.7K |
 VYGR | Voyager Therapeutics, Inc. Common Stock | $224.7m | $3.60 | -4.3% | 565.5K |
 TNXP | Tonix Pharmaceuticals Holding Corp. | $180.6m | $14.37 | -8.7% | 383.4K |
 ABOS | Acumen Pharmaceuticals, Inc. Common Stock | $177.7m | $2.15 | -5.9% | 267.6K |